Document is current
Any future updates will be listed below
-
Authors
Hunter Gibble, Theresa https://orcid.org/0000-0001-8412-9175
Cao, Dachuang
Zhang, Xiaotian Michelle
Xavier, Neena Agarwal
Poon, Jiat Ling
Fitch, Angela
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04657003 at ClinicalTrials.govDocuments that mention this clinical trial
Tirzepatide Was Associated with Improved Health-Related Quality of Life in Adults with Obesity or Overweight and Type 2 Diabetes: Results from the Phase 3 SURMOUNT-2 Trial
https://doi.org/10.1007/s13300-025-01723-w
-
Funding
Funding for this research was provided by:
Eli Lilly and Company
- License Information
-
More Information
Article History
Received: 17 December 2024
Accepted: 4 March 2025
First Online: 22 March 2025
Declarations
:
: Theresa Hunter Gibble, Dachuang Cao, Xiaotian Michelle Zhang, Neena Agarwal Xavier and Jiat Ling Poon are employees and shareholders of Eli Lilly and Company. Angela Fitch reports personal fees from Eli Lilly and Company, Novo Nordisk, Rhythm, Currax, Neurobo, Nestle, Jenny Craig, Sidekick, Abbvie, Carmot, and Vivus and non-financial support from Seca during the conduct of the study.
: The study protocol was approved by local institutional review boards and adhered to the principles outlined in the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines. All participants provided written informed consent prior to the study.
